Subsequent analysis of CD86 and CD163 mRNA expression in TAMs cocultured with cancer cells revealed that ANXA2 knockdown increased CD86 expression but suppressed CD163 expression compared with those in the control group. The gene discussed is CD163; the disease is cancer.